Literature DB >> 31418028

The physiological phenotype of obstructive sleep apnea differs between Caucasian and Chinese patients.

Denise M O'Driscoll1,2, Shane A Landry3,4,5, Jonathan Pham1, Alan Young1,2, Scott A Sands6, Garun S Hamilton7,8,9, Bradley A Edwards3,4,5.   

Abstract

STUDY
OBJECTIVES: The mechanisms responsible for the development of obstructive sleep apnea (phenotypic "traits") are known to differ between individuals and may differ across ethnicities. We aimed to examine whether loop gain, arousal threshold, pharyngeal collapsibility and muscle compensation differ between Chinese and Caucasian individuals with OSA.
METHODS: We noninvasively determined the relative contribution of loop gain, arousal threshold, pharyngeal collapsibility, and muscle compensation from the ventilatory flow pattern recorded during a standard clinical polysomnography in a cohort of age and AHI matched Caucasian and Chinese patients with moderate-severe OSA (n = 90).
RESULTS: Chinese participants had significantly more collapsible pharyngeal airways as indicated by a lower Vpassive (68.9 [51.5-75.2] vs. 74.0 [65.1-80.4] %Veupnea, U = 703, p = 0.012), but less ventilatory control instability as indicated by a lower loop gain (0.60 [0.50-0.67] vs. 0.63 [0.57-0.81], U = 762, p = 0.043) compared with Caucasian participants. Further, multiple logistic regression analyses demonstrated that the combined pharyngeal collapsibility (Vpassive) and loop gain traits help to better explain the differences between the groups beyond upper-airway collapsibility alone. No statistically significant group differences were found in muscle compensation or arousal threshold traits between groups.
CONCLUSION: Individuals of Chinese descent appear to have OSA that is driven much more by the relative contribution of their anatomical predisposition and to a lesser extent nonanatomical causes compared with Caucasians. Future research should focus on determining if Chinese versus Caucasian ethnicity is an important contributing factor to clinical outcomes and therapeutic responses in OSA. © Sleep Research Society 2019. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com.

Entities:  

Keywords:  pathophysiology; collapsibility; ethnicity; loop gain; race

Mesh:

Year:  2019        PMID: 31418028     DOI: 10.1093/sleep/zsz186

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  11 in total

1.  Variations in loop gain and arousal threshold during NREM sleep are affected by time of day over a 24-hour period in participants with obstructive sleep apnea.

Authors:  Shipra Puri; Mohamad El-Chami; David Shaheen; Blake Ivers; Gino S Panza; M Safwan Badr; Ho-Sheng Lin; Jason H Mateika
Journal:  J Appl Physiol (1985)       Date:  2020-08-13

2.  Differences in three-dimensional upper airway anatomy between Asian and European patients with obstructive sleep apnea.

Authors:  Liyue Xu; Brendan T Keenan; Andrew S Wiemken; Luqi Chi; Bethany Staley; Zhifang Wang; Jianjun Wang; Bryndis Benedikstdottir; Sigurdur Juliusson; Allan I Pack; Thorarinn Gislason; Richard J Schwab
Journal:  Sleep       Date:  2020-05-12       Impact factor: 5.849

3.  Point-of-care prediction model of loop gain in patients with obstructive sleep apnea: development and validation.

Authors:  Christopher N Schmickl; Jeremy E Orr; Paul Kim; Brandon Nokes; Scott Sands; Sreeganesh Manoharan; Lana McGinnis; Gabriela Parra; Pamela DeYoung; Robert L Owens; Atul Malhotra
Journal:  BMC Pulm Med       Date:  2022-04-25       Impact factor: 3.320

4.  Pathogenesis of obstructive sleep apnea in people living with HIV.

Authors:  Jeremy E Orr; Bradley A Edwards; Christopher N Schmickl; Maile Karris; Pamela N DeYoung; Chantal Darquenne; Rebecca Theilmann; Sonia Jain; Atul Malhotra; Charles B Hicks; Robert L Owens
Journal:  J Appl Physiol (1985)       Date:  2021-10-21

5.  Primary aldosteronism is highly prevalent in patients with hypertension and moderate to severe obstructive sleep apnea.

Authors:  Piotr Dobrowolski; Sylwia Kołodziejczyk-Kruk; Ewa Warchoł-Celińska; Marek Kabat; Urszula Ambroziak; Aleksandra Wróbel; Piotr Piekarczyk; Aleksandra Ostrowska; Magdalena Januszewicz; Paweł Śliwiński; Jacques W M Lenders; Andrzej Januszewicz; Aleksander Prejbisz
Journal:  J Clin Sleep Med       Date:  2021-04-01       Impact factor: 4.062

6.  Use and Performance of the STOP-Bang Questionnaire for Obstructive Sleep Apnea Screening Across Geographic Regions: A Systematic Review and Meta-Analysis.

Authors:  Bianca Pivetta; Lina Chen; Mahesh Nagappa; Aparna Saripella; Rida Waseem; Marina Englesakis; Frances Chung
Journal:  JAMA Netw Open       Date:  2021-03-01

7.  Differences in Predicted Therapeutic Outcome of Mandibular Advancement Determined by Remotely Controlled Mandibular Positioner in Canadian and Chinese Apneic Patients.

Authors:  Wei Wang; Frédéric Sériès; Wen-Yang Li; Jean-Francois Masse; Simon Gakwaya; Zhenjin Zhao
Journal:  Nat Sci Sleep       Date:  2022-09-08

8.  A single dose of noradrenergic/serotonergic reuptake inhibitors combined with an antimuscarinic does not improve obstructive sleep apnoea severity.

Authors:  Luke D J Thomson; Shane A Landry; Simon A Joosten; Dwayne L Mann; Ai-Ming Wong; Tim Cheung; Mulki Adam; Caroline J Beatty; Garun S Hamilton; Bradley A Edwards
Journal:  Physiol Rep       Date:  2022-08

9.  Acetazolamide for OSA and Central Sleep Apnea: A Comprehensive Systematic Review and Meta-Analysis.

Authors:  Christopher N Schmickl; Shane A Landry; Jeremy E Orr; Kazuo Chin; Kimihiko Murase; Johan Verbraecken; Shahrokh Javaheri; Bradley A Edwards; Robert L Owens; Atul Malhotra
Journal:  Chest       Date:  2020-08-05       Impact factor: 9.410

10.  Forkhead Box P3 Methylation and Expression in Men with Obstructive Sleep Apnea.

Authors:  David Sanz-Rubio; Arianne Sanz; Luis Varona; Rosa Bolea; Marta Forner; Ana V Gil; Pablo Cubero; Marta Marin-Oto; Inmaculada Martin-Burriel; Jose M Marin
Journal:  Int J Mol Sci       Date:  2020-03-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.